Abstract

Speaker Biography: Professor Bin Tean Teh obtained his M.D. from the University of Queensland, Australia and his Ph.D. from the Karolinska Institute, Sweden. Following postdoctoral works in multiple endocrine neoplasia 1 at Karolinska Institute, Prof. Teh joined the Van Andel Research Institute (VARI) in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. In 2007, Prof. Teh was appointed the founding Director of the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010, he received the STaR award and relocated to Singapore and is currently a full professor. His laboratory focuses on genomic studies of cancers common among Asian populations, using tools such as high-throughput genomic platforms and correlation studies with clinico-pathological information. In the last three years, his group, in collaboration with others, has made significant advances in bile duct cancer, T-cell lymphoma, and kidney cancer. Moving forward, his lab will shift emphasis to downstream works including transgenic animal modeling, synthethic lethal screening, and other functional studies in cancer. Prof. Teh has published extensively over 290 publications in high impact scientific journals.